2022
DOI: 10.6002/ect.2022.0080
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…72 Octreotide was also studied as an agent with renal benefits in patients undergoing LT. Bagheri Lankarani and associates performed a randomized, double-blind, placebo-controlled clinical trial on 50 patients who underwent deceased donor LTs. 73 They received either an octreotide infusion for the first 3 days after the transplant or a placebo. Acute kidney injury, EAD, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group.…”
Section: Renal Issuesmentioning
confidence: 99%
“…72 Octreotide was also studied as an agent with renal benefits in patients undergoing LT. Bagheri Lankarani and associates performed a randomized, double-blind, placebo-controlled clinical trial on 50 patients who underwent deceased donor LTs. 73 They received either an octreotide infusion for the first 3 days after the transplant or a placebo. Acute kidney injury, EAD, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group.…”
Section: Renal Issuesmentioning
confidence: 99%